Open AccessThe Improvement of INS Gene Sequences on Rat Model of Type 1 Diabetes in Goat Milk Casein Protein Treatment, but not in Glibenclamide
Author(s) -
M.Si. Dra. Mulyati,
Elzafa Y Mu'jizah,
F. Fatchiyah
Publication year - 2019
Publication title -
journal of physics. conference series
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 85
eISSN - 1742-6596
pISSN - 1742-6588
DOI - 10.1088/1742-6596/1374/1/012043
Subject(s) - glibenclamide , diabetes mellitus , type 2 diabetes , biology , gene , endocrinology , pharmacology , medicine , biochemistry
This study was aimed to determine the effect of CSN1S2 protein from Etawah Crossbred goat milk for repairing DNA sequence of INS gene in T1DM rat model. We divided the experimental rats into control group, diabetes group, control with CSN1S2 protein treatment group, diabetes with CSN1S2 protein treatment group, and diabetes with glibenclamide treatment group. The dose of CSN1S2 protein and glibenclamide used was 800 mg/kg BW and 5 mg/kg BW, respectively. We isolated the DNA from rat pancreas tissue and amplified it with a specific primer of INS gene. Our study investigated that there were transition, transversion, and deletion mutation in diabetic rat. The glibenclamide administration had changed 6 point mutations in INS of the diabetic rat to normal, but it created the other 9 new mutations. The CSN1S2 protein treatment showed mutation repairing in INS of diabetes group. Consequently, CSN1S2 have potential effect as anti-diabetes and is safe to consume than glibenclamide.